You are here: Home / Infrastructures / Res. Infrastructure
INGESTEM - First French consortium of therapeutic innovations based on induced pluripotent stem cells (iPS cells) and human tissue engineering (INGESTEM)
Hosting Legal Entity
French National Institute of Health and Medical Research (INSERM)
16 avenue Paul Vaillant Couturier, Villejuif (France)
Institut André Lwoff - Bâtiment A - 7, rue Guy Môquet, U935 INSERM / ESTeam Paris-Sud, Villejuif, PO: 94800, Île-de-France (France)
Type Of RI
Coordinating Country
Provider Country:
ESTeam Paris-Sud | I-Stem | Instruct Center - France 1 - Institute of Genetics and Molecular and Cellular Biology (IGBMC) | IRMB - Safe iPS | SBRI - PrimaStem
Current Status:
Operational since 2015
Being upgraded since 2019 to 2019
Under construction since 2013 to 2015
Scientific Description
Our missions are to explore the medical and industrial potential of iPS cells, and to bring innovative technology solutions by providing expertise in all stages of project development and translation.INGESTEM aims to coordinate and structure different steps involved in the development stem cells used either for drug screening or for protocols of regenerative medicine with the following strategies:- Creation of a “research” biobank of human and animal induced pluripotent stem cells (iPS) and embryonic stem cells (ES)- Development of a french registry of iPS cell lines qualified with international standards, including clinical and biological annotations- Cell and tissue engineering- Risk analysis and characterization of products from cell engineering- Standardization of protocols and automated production- Transgenic animal models- Modeling of human monogenic and polygenic genetic diseases, drug discovery by high throughput screening.- Therapeutic models with design and validation of preclinical models to the production of Advanced-Therapy Medicinal Products (ATMPs) for early clinical trials phase I-II.

RI Keywords
Biobank, Cell based high content screening, Animal models, Induced pluripotent stem cells (iPSCs), Regenerative medicine, Stem cells, Embryonic stem cells (ESC)
RI Category
Cell Culture Facilities
Scientific Domain
Biological and Medical Sciences
ESFRI Domain
Health and Food
Drug Discovery

High-throughput screening.

Cell Engineering

On demand cell differentiation; Genome editing; Generation of iPS cell line; Quality control tests.

Date of last update: 28/05/2018
Printable version